Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Genextra

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 8
Average round size
info
The average size of a deal this fund participated in
$31M
Portfolio companies 3
Rounds per year 0.38
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.62
Exits 1
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Health Care
  • Biotechnology
  • Pharmaceutical
  • Medical
Summary

Genextra appeared to be the Corporate Investor, which was created in 2003. The venture was found in Europe in Italy. The leading representative office of defined Corporate Investor is situated in the Milan.

Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Biotechnology. The fund has specific favorite in a number of founders of portfolio startups. Among the most popular portfolio startups of the fund, we may highlight Erydel, Intercept Pharmaceuticals. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Italy.

Comparing to the other companies, this Genextra performs on 4 percentage points more the average number of lead investments. The high activity for fund was in 2018. The increased amount of exits for fund were in 2012. The fund is constantly included in less than 2 investment rounds annually. Considering the real fund results, this Corporate Investor is 47 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars.

The standard case for the fund is to invest in rounds with 1-2 partakers. Despite the Genextra, startups are often financed by Innogest Capital, FM Management. The meaningful sponsors for the fund in investment in the same round are Sofinnova Partners, Innogest Capital. In the next rounds fund is usually obtained by OrbiMed.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Genextra:
Typical Co-investors
Genextra is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Genextra:
There are no funds here. If we find new data, we will add it here.

Funds with similar focus

Funds from Italy
Funds with similar focus located in Italy:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Carl Zeiss Meditec Germany, Jena, Thuringen
Chunde Touzi China, Shanghai
Junglee California, Sunnyvale, United States
marquee angels -
Otto Capital Seattle, United States, Washington
Qingzhe Capital -
Realtime ventures LLP Gurgaon, Haryana, India
The Untitled Venture Company California, San Francisco, United States
Volkswagen Financial Services Herndon, United States, Virginia
Yunlin China, Jiading District

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

InnovHeart

Health Care
Medical
$55M27 Jan 2022 Milan, Lombardy, Italy

InnovHeart

Health Care
Medical
$23M07 Aug 2020 Italy, Lombardy

Erydel

Biotechnology
Health Care
Pharmaceutical
$31M24 Apr 2018 Campobasso, Molise, Italy

Erydel

Biotechnology
Health Care
Pharmaceutical
$17M01 Jul 2013 Campobasso, Molise, Italy

Intercept Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$30M10 Aug 2012 New York, New York, United States

Intercept Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$25M25 Jan 2010 New York, New York, United States

Intercept Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$25M29 Jul 2008 New York, United States

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Genextra?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 8
Average round size 31M
Rounds per year 0.38
Peak activity year 2018
Lead investments 2
Follow on index 0.62
Exits 1
Group Appearance index 0.75

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

InnovHeart

Health Care
Medical
$55M27 Jan 2022 Milan, Lombardy, Italy

InnovHeart

Health Care
Medical
$23M07 Aug 2020 Italy, Lombardy

Erydel

Biotechnology
Health Care
Pharmaceutical
$31M24 Apr 2018 Campobasso, Molise, Italy

Erydel

Biotechnology
Health Care
Pharmaceutical
$17M01 Jul 2013 Campobasso, Molise, Italy

Intercept Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$30M10 Aug 2012 New York, New York, United States

Intercept Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$25M25 Jan 2010 New York, New York, United States

Intercept Pharmaceuticals

Biotechnology
Health Care
Pharmaceutical
$25M29 Jul 2008 New York, United States
Crunchbase icon

Content report

The following text will be sent to our editors: